person · Reporting owner
OLDAKOWSKI JOSEPH FRANK
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CLOVER HEALTH INVESTMENTS, CORP. /DECLOV · Entity 4419 | VP OF FINANCE AND CONTROLLER | September 16, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CLOVER HEALTH INVESTMENTS, CORP. /DE
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 275,897 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 3,170 · Balance 275,897 F1: The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 17, 2026 21:29 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | SaleClass A Common Stock | 3,170 | $4.64 | $14,708.80 |
DisclosureSEC source: 0001801170-26-000223 · wk-form4_1789680572.xml · nonDerivative · entry 1 OLDAKOWSKI JOSEPH FRANK · CIK 0002128814 · VP OF FINANCE AND CONTROLLER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,897 F1 · shares: The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 00:52 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | SaleClass A Common Stock | 20,000 | $5.16 | $103,200.00 |
DisclosureSEC source: 0001801170-26-000218 · wk-form4_1789433557.xml · nonDerivative · entry 1 OLDAKOWSKI JOSEPH FRANK · CIK 0002128814 · VP OF FINANCE AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,067 Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 12:13 UTC | CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV · Entity 4419 | SaleClass A Common Stock | 12,102 | $4.86 | $58,815.72 |
DisclosureSEC source: 0001801170-26-000161 · wk-form4_1781698407.xml · nonDerivative · entry 1 OLDAKOWSKI JOSEPH FRANK · CIK 0002128814 · VP OF FINANCE AND CONTROLLER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 299,067 F1 · kind: The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.